Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amarin, a late-stage biopharmaceutical company, has dosed first patient in REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial), the cardiovascular outcomes study utilizing AMR101.
Subscribe to our email newsletter
The multinational, prospective, randomized, double-blind study will evaluate the effectiveness of AMR101 in reducing the prevalence of first major cardiovascular events in a high-risk patient population.
Amarin chairman and CEO Joseph Zakrzewski said that the results of REDUCE-IT may enable them to seek additional indications for AMR101 including cardiovascular prevention.